Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare
IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, “LabCorp” (NYSE: LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product.
Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world’s largest diagnostics clinical laboratories, boasting $7B in annual revenues, over 2,000 locations, and a workforce of 36,000 employees.
"I'm excited to work closely with Zack and Jack to drive the expansion of Biomerica’s exciting new inFoods IBS product and the recently FDA-cleared HP Detect® product for sale in the US,” said Mr. Huff.
Zack Irani, CEO of Biomerica, expressed confidence in Mr. Huff’s appointment, stating, “Gary's remarkable career in healthcare and clinical laboratories, particularly as LabCorp’s Diagnostics CEO, showcases his exceptional abilities. His leadership contributed to notable growth at LabCorp. Gary brings not only a rich background in commerce, but also crucial connections within the medical diagnostic field. As we introduce inFoods IBS both in the U.S. and abroad, we are confident that Gary's insights in the industry will be incredibly beneficial."
About Biomerica (NASDAQ: )
Biomerica, Inc. () is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primary focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company’s inFoods® IBS test and other tests, FDA clearance or possible future clearance of the Company’s products, timing of the commercial launch of the Company’s products, the efficacy of the Company’s products, possible future revenues from the sale of the Company’s products, growth in future revenues from the sale of the Company’s products, acceptance of the Company’s products by physicians and their patients, any future FDA marketing authorization, the uniqueness of the Company’s products, pricing of the Company’s products, future possible insurer reimbursement for the Company’s products, patent protection on the Company’s products and the underlying technology of the products, current or future competition for the Company’s products from other medical manufacturers or distributors. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated financial and other results in the future. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact:
Zack Irani
949-645-2111
Source: Biomerica, Inc.
